Chipscreen(SH:688321) Sou Hu Cai Jing·2026-01-27 16:45Core Viewpoint - Microchip Biotech (688321) is expected to achieve significant revenue growth in 2025, driven by strong sales of its products, particularly Seglitazone and the inclusion of a new indication for Sidabamine in the national medical insurance directory [1][2]. Trading Information Summary - On January 27, Microchip Biotech closed at 33.6 yuan, down 2.3%, with a turnover rate of 4.03%, a trading volume of 164,300 shares, and a transaction value of 547 million yuan [1]. - The net outflow of main funds was 71.25 million yuan, accounting for 13.02% of the total transaction value [2]. Fund Flow Summary - Retail investors showed a net inflow of 68.55 million yuan, representing 12.53% of the total transaction value, while speculative funds had a net inflow of 2.70 million yuan, making up 0.49% of the total transaction value [1]. Company Announcement Summary - Microchip Biotech forecasts a revenue of approximately 910.08 million yuan for 2025, reflecting a year-on-year growth of about 38.32% [1]. - The company anticipates a net profit attributable to shareholders of around 53.46 million yuan, marking a significant turnaround from a loss, with a year-on-year increase of approximately 168.03 million yuan [1]. - The growth in performance is primarily attributed to a 123% increase in sales revenue from Seglitazone and the sales boost from Sidabamine's new indication being included in the national medical insurance directory [1][2].